TAS 102 mechanism of action compared to 5-FU
Descrição
Efficacy of Combination Chemotherapy Using a Novel Oral
TAS-102, a novel antitumor agent: A review of the mechanism of
TAS-102 with or without bevacizumab in patients with
5-Fluorouracil (5-FU) resistance and the new strategy to enhance
Redefining Later-Line Therapy in Metastatic Colorectal Cancer - EMJ
Phase I study of TAS-102 treatment in Japanese patients with
Inhibitory activity of FTD and 5-FU against cancer cells sensitive
Efficacy of trifluridine and tipiracil (TAS-102) versus placebo
TAS-102 plus bevacizumab for patients with metastatic colorectal
de
por adulto (o preço varia de acordo com o tamanho do grupo)
